Literature DB >> 30603667

Heavy Drinking and Treatment among HIV/HCV Co-Infected Patients.

Jennifer C Elliott1,2, Noga Shalev3, Deborah S Hasin1,2,4.   

Abstract

AIMS: Given the efficacy of new medications for Hepatitis C virus (HCV), we aimed to determine whether drinking relates to HCV treatment access among the high-risk group of individuals with HIV/HCV co-infection.
METHODS: We sampled 210 patients in a sexual health clinic; of these, 39 reported HIV/HCV co-infection (79.49% male; 56.41% Black). Patients completed a self-report survey on drinking and treatment history.
RESULTS: Those drinking despite health problems reported less HCV treatment (p =0.035). Drinking despite health problems did not relate to whether HCV treatment was recommended by providers, and binge drinking did not relate to either HCV outcome. Drinking was unrelated to HIV treatment.
CONCLUSIONS: HIV/HCV co-infected individuals drinking despite health problems are in urgent need of attention, to reduce drinking and increase engagement in treatment. Drinking despite health problems m ay serve as an effective screening question to identify HIV/HCV co-infected drinkers who are most at risk of being untreated.

Entities:  

Keywords:  Alcohol; Drinking; HIV; Hepatitis C; Treatment

Year:  2018        PMID: 30603667      PMCID: PMC6312191     

Source DB:  PubMed          Journal:  J Subst Abus Alcohol        ISSN: 2373-9363


  9 in total

1.  Alcohol use among patients with HIV infection.

Authors:  Maurizio Bonacini
Journal:  Ann Hepatol       Date:  2011 Oct-Dec       Impact factor: 2.400

2.  Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States.

Authors:  Soumitri Barua; Robert Greenwald; Jason Grebely; Gregory J Dore; Tracy Swan; Lynn E Taylor
Journal:  Ann Intern Med       Date:  2015-08-04       Impact factor: 25.391

3.  Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virologic response to interferon therapy.

Authors:  Yoshiaki Iwasaki; Kouichi Takaguchi; Hiroshi Ikeda; Yasuhiro Makino; Yasuyuki Araki; Masaharu Ando; Haruhiko Kobashi; Toshitsugu Kobatake; Ryoji Tanaka; Minoru Tomita; Tomonori Senoh; Mitsuhiko Kawaguchi; Toshinari Shimoe; Koji Manabe; Keiji Kita; Junnosuke Shimamura; Kohsaku Sakaguchi; Yasushi Shiratori
Journal:  Liver Int       Date:  2004-12       Impact factor: 5.828

4.  Risky alcohol use and serum aminotransferase levels in HIV-infected adults with and without hepatitis C.

Authors:  Judith I Tsui; Debbie M Cheng; Howard Libman; Carly Bridden; Richard Saitz; Jeffrey H Samet
Journal:  J Stud Alcohol Drugs       Date:  2013-03       Impact factor: 2.582

5.  Short article: Alcohol and substance use, race, and insurance status predict nontreatment for hepatitis C virus in the era of direct acting antivirals: a retrospective study in a large urban tertiary center.

Authors:  Omar T Sims; Yuqi Guo; Mohamed G Shoreibah; Krishna Venkata; Paul Fitzmorris; Vishnu Kommineni; John Romano; Omar I Massoud
Journal:  Eur J Gastroenterol Hepatol       Date:  2017-11       Impact factor: 2.566

Review 6.  Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C?

Authors:  Youngmin A Lee; Scott L Friedman
Journal:  Antiviral Res       Date:  2014-04-12       Impact factor: 5.970

Review 7.  HIV and hepatitis C virus: special concerns for patients with cirrhosis.

Authors:  Michael P Curry
Journal:  J Infect Dis       Date:  2013-03       Impact factor: 5.226

Review 8.  Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review.

Authors:  Oluwaseun Falade-Nwulia; Catalina Suarez-Cuervo; David R Nelson; Michael W Fried; Jodi B Segal; Mark S Sulkowski
Journal:  Ann Intern Med       Date:  2017-03-21       Impact factor: 25.391

9.  Awareness of hepatitis C diagnosis is associated with less alcohol use among persons co-infected with HIV.

Authors:  Judith I Tsui; Richard Saitz; Debbie M Cheng; David Nunes; Howard Libman; Julie K Alperen; Jeffrey H Samet
Journal:  J Gen Intern Med       Date:  2007-02-23       Impact factor: 5.128

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.